Madrigal Pharmaceuticals, Inc.
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| metabolic | ×1.38 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| preclinical | ×1.38 | 3 |
Strategy profile
Based on 3 disclosed transactions, Madrigal Pharmaceuticals, Inc. concentrates its licensing activity in Metabolic, Gastroenterology. Madrigal Pharmaceuticals, Inc. pays a 1.38x premium over market median, with the strongest premiums in Metabolic (1.38x). Their most common deal structure is License, with an average disclosed value of $2.5B. Most recent activity: 2026.
Premium by therapeutic area
How Madrigal Pharmaceuticals, Inc. pays relative to peer medians in each TA
Pipeline coverage & gaps
Madrigal Pharmaceuticals, Inc. has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 3 | $90M | $2.5B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | siRNA candidate for MASH | Arrowhead Pharmaceuticals | MASH (metabolic dysfunction-associated steatohepatitis) | unknown | — | $1.0B |
| 2025 | SYH2086 | CSPC Pharmaceutical | MASH | preclinical | $120M | $2.1B |
| 2025 | siRNA MASH portfolio | Ribo Life Science | MASH/NASH | preclinical | $60M | $4.4B |
How this is computed
For each Madrigal Pharmaceuticals, Inc. deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 1.384, clamped to [0.7, 1.5].